• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes.
【24h】

The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes.

机译：主要的马过敏原Equ c 1包含一个T细胞表位的免疫主要区域。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Despite the fact that most significant mammalian respiratory allergens are lipocalin proteins, information on the human T cell reactivity to these allergenic proteins is largely missing. OBJECTIVE: Knowing the T cell epitopes in allergens is a prerequisite for developing novel preparations for allergen immunotherapy. METHODS: Specific T cell lines were generated with recombinant Equ c 1 from the peripheral blood mononuclear cells (PBMCs) of 10 horse-allergic subjects. For determining T cell epitopes, the lines were stimulated with 16mer synthetic Equ c 1 peptides overlapping by 14 amino acids. The binding capacity of Equ c 1 peptides to human leucocyte antigen class II molecules was determined by the competitive ELISA. RESULTS: The major horse allergen Equ c 1 resembles two other lipocalin allergens, the major cow allergen Bos d 2 and the major dog allergen Can f 1, in that it is weakly stimulatory for the PBMCs of sensitized subjects. Moreover, the T cell epitopes of Equ c 1 are clustered in a few regions along the molecule, as is the case with Bos d 2 and Can f 1. Similar to Bos d 2, Equ c 1 contains one immunodominant epitope region at the carboxy-terminal end of the molecule. The T cell lines of eight horse-allergic subjects out of 10 showed strong reactivity to one or both of the two overlapping peptides, p143-158 and p145-160, in this region. The region probably contains two overlapping epitopes. CONCLUSION: The 18mer peptide p143-160 from the immunodominant region of Equ c 1 is a potential candidate for the peptide-based immunotherapy of horse-sensitized subjects.
机译：背景：尽管最重要的哺乳动物呼吸道过敏原是脂钙蛋白，但有关人类T细胞与这些过敏原蛋白反应性的信息却很少。目的：了解变应原中的T细胞表位是开发变应原免疫疗法新制剂的先决条件。方法：用重组Equ c 1从10名马过敏性受试者的外周血单核细胞（PBMC）中产生特异性T细胞系。为了确定T细胞表位，用重叠有14个氨基酸的16mer合成Equ c 1肽刺激品系。通过竞争性ELISA确定Equ c 1肽与人白细胞抗原II类分子的结合能力。结果：主要的马过敏原Equ c 1与另外两种脂钙素过敏原类似，主要的牛过敏原Bos d 2和主要的犬过敏原Can f 1，因为它对敏感对象的PBMC具有微弱的刺激作用。而且，Equ c 1的T细胞抗原决定簇聚集在分子的几个区域，就像Bos d 2和Can f 1的情况一样。与Bos d 2相似，Equ c 1在羧基处含有一个免疫显性抗原决定部位-分子的末端。 10位中的8位马过敏性受试者的T细胞系对该区域的两个重叠肽p143-158和p145-160中的一个或两个显示强反应性。该区域可能包含两个重叠的表位。结论：来自Equ c 1免疫优势区域的18mer肽p143-160是马致敏对象基于肽的免疫治疗的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号